AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

NCT06767527 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

416

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer (TNBC)

Interventions

DRUG: AK112
DRUG: Nab-paclitaxel
DRUG: Placebo

Sponsor

Akeso